MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Danaher Corp

Închisă

SectorSănătate

197.94 -3.52

Rezumat

Modificarea prețului

24h

Curent

Minim

197.71

Maxim

204.96

Indicatori cheie

By Trading Economics

Venit

268M

1.1B

Vânzări

738M

6.5B

P/E

Medie Sector

38.752

63.778

EPS

2.14

Randament dividend

0.62

Marjă de profit

16.611

Angajați

61,000

EBITDA

-230M

1.4B

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+28.05% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

0.62%

2.39%

Următoarele câștiguri

22 apr. 2025

Data viitoare de dividende

25 apr. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-16B

147B

Deschiderea anterioară

201.46

Închiderea anterioară

197.94

Sentimentul știrilor

By Acuity

33%

67%

106 / 386 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Strong Bearish Evidence

Danaher Corp Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

5 feb. 2025, 12:54 UTC

Câștiguri

Johnson Controls Names Weidemanis CEO, Logs 1Q Income Growth

29 ian. 2025, 11:44 UTC

Câștiguri

Danaher 4Q Revenue Rises on Gains in Life Sciences, Biotech

22 oct. 2024, 10:35 UTC

Câștiguri

Danaher 3Q EPS, Sales Top Views on Strong Cepheid Test Demand

23 iul. 2024, 10:55 UTC

Câștiguri

Danaher Expects 3Q Core Sales Drop, Backs 2024 Guidance

29 ian. 2025, 15:25 UTC

Market Talk
Câștiguri

Danaher's 2025 Sales Guidance Disappoints -- Market Talk

29 ian. 2025, 13:56 UTC

Top știri
Câștiguri

Danaher Had an Unusual Quarter. The Stock Is Down. -- Barrons.com

29 ian. 2025, 11:08 UTC

Câștiguri

Danaher Sees 2025 Bioprocessing Core Revenue Growth 6%-7% >DHR

29 ian. 2025, 11:07 UTC

Câștiguri

Danaher Sees 2025 Adjusted Operating Profit Margin About 28.5% >DHR

29 ian. 2025, 11:07 UTC

Câștiguri

Danaher: Expect to Return to Growth, Build Back to Normal Market Conditions in 2025 >DHR

29 ian. 2025, 11:02 UTC

Câștiguri

Danaher Sees 2025 Adjusted Core Revenue Up About 3% >DHR

29 ian. 2025, 11:01 UTC

Câștiguri

Danaher Sees 1Q Adjusted Core Revenue Down Low-Single Digits >DHR

29 ian. 2025, 11:01 UTC

Câștiguri

Danaher 4Q Operating Cash Flow $2B, Free Cash Flow $1.5B >DHR

29 ian. 2025, 11:00 UTC

Câștiguri

Danaher 4Q Adjusted Core Revenue Rose 1% >DHR

29 ian. 2025, 11:00 UTC

Câștiguri

Danaher 4Q Cont Ops EPS $1.49 >DHR

29 ian. 2025, 11:00 UTC

Câștiguri

Danaher 4Q Net $1.09B >DHR

29 ian. 2025, 11:00 UTC

Câștiguri

Danaher 4Q EPS $1.49 >DHR

29 ian. 2025, 11:00 UTC

Câștiguri

Danaher 4Q Adj EPS $2.14 >DHR

29 ian. 2025, 11:00 UTC

Câștiguri

Danaher 4Q Sales $6.5B >DHR

22 oct. 2024, 10:02 UTC

Câștiguri

Danaher 3Q Adjusted Core Revenue Rose 0.5% >DHR

22 oct. 2024, 10:02 UTC

Câștiguri

Danaher Still Sees 2024 Adjusted Core Revenue Down Low-Single Digits >DHR

22 oct. 2024, 10:01 UTC

Câștiguri

Danaher Sees 4Q Adjusted Core Revenue Down Low-Single Digits >DHR

22 oct. 2024, 10:00 UTC

Câștiguri

Danaher 3Q Operating Cash Flow $1.5B, Adjusted Free Cash Flow $1.2B >DHR

22 oct. 2024, 10:00 UTC

Câștiguri

Danaher 3Q Sales $5.8B >DHR

22 oct. 2024, 10:00 UTC

Câștiguri

Danaher 3Q EPS $1.12 >DHR

22 oct. 2024, 10:00 UTC

Câștiguri

Danaher 3Q Adj EPS $1.71 >DHR

22 oct. 2024, 10:00 UTC

Câștiguri

Danaher 3Q Net $818M >DHR

22 oct. 2024, 10:00 UTC

Câștiguri

Danaher 3Q Cont Ops EPS $1.12 >DHR

23 iul. 2024, 12:39 UTC

Top știri
Câștiguri

Danaher Stock Surges. More Than Earnings Are Driving It Higher. -- Barrons.com

23 iul. 2024, 10:05 UTC

Câștiguri

Danaher 2Q Adjusted Core Revenue Fell 3.5% >DHR

23 iul. 2024, 10:05 UTC

Câștiguri

Danaher Sees 2024 Adjusted Core Revenue Down Low-Single Digits >DHR

Comparație

Modificare preț

Danaher Corp Așteptări

Obiectiv de preț

By TipRanks

28.05% sus

Prognoză pe 12 luni

Medie 262.71 USD  28.05%

Maxim 300 USD

Minim 240 USD

În baza a 17 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruDanaher Corp - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

17 ratings

13

Cumpărare

4

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

199.78 / 210.26Suport & Rezistență

Termen scurt

Strong Bearish Evidence

Termen mediu

Weak Bearish Evidence

Termen lung

Bearish Evidence

Sentiment

By Acuity

106 / 386 Clasament în Sănătate

Sentimentul știrilor

Evidențe de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Danaher Corp

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands. The Diagnostics segment offers chemistry, immunoassay, microbiology, and automation systems; and molecular, acute care, and pathology diagnostics products. This segment also provides clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company has a research collaboration with Stanford University's Department of Bioengineering for cancer drug development. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is based in Washington, the District of Columbia.